ProRelix Services LLP is proud to announce its official registration with the Central Drugs Standard Control Organization (CDSCO), India’s premier national regulatory authority for pharmaceuticals and clinical trials.
This milestone underscores our dedication to regulatory excellence, ensuring that every clinical trial we conduct meets the highest standards of safety, ethics, and compliance. With CDSCO registration, ProRelix Research strengthens its ability to seamlessly manage and execute global trials across diverse regulatory landscapes, including the US, EU, and APAC regions.
Our clients can now benefit from an even more robust framework for regulatory submissions, trial approvals, and monitoring, backed by our expertise in complex international requirements. This achievement further positions ProRelix Services as a trusted partner for sponsors, delivering quality-driven, compliant, and efficient clinical research solutions.
For sponsors seeking a reliable CRO partner with proven regulatory credentials, ProRelix Research stands ready to help bring innovative therapies to market faster, while ensuring patient safety remains the top priority.
Be the first to know the latest trends in clinical research, real-world case studies, and industry secrets.
ProRelix Research is the rapidly growing Contract/ Clinical Research Organization (CRO) with multi-country service capability supporting phase 1, 2, 3, & 4 clinical trials of Pharma, Biotech, Biopharma, Medical Device, Nutraceutical & Herbal companies to conduct in the USA, India, Europe & South East Asia.